Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health, Inc. (NYSE: TDOC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its virtual care business, financial condition and governance. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe material events, segment performance and capital structure decisions.
Recent Form 8-K filings for Teladoc Health have addressed topics such as quarterly financial results, preliminary earnings announcements, entry into a senior secured revolving credit facility, amendments to the company’s 2023 Employment Inducement Incentive Award Plan, and changes in executive leadership and Board composition. For example, the company has reported on its second and third quarter 2025 results, including revenue by type and geography, Integrated Care and BetterHelp segment performance, and adjusted EBITDA. It has also disclosed the establishment of a five-year revolving credit facility and amendments to its inducement equity plan to increase the number of shares reserved for issuance.
On this page, investors can review Teladoc Health’s SEC filings to understand how the company reports revenue from access fees and other sources, how it presents non-GAAP measures such as adjusted EBITDA, and how it describes its capital allocation priorities. Filings also provide information on leadership transitions, director decisions, and compensatory arrangements, including inducement awards of restricted stock units and performance stock units.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports. Users can quickly see highlights related to Teladoc Health’s Integrated Care and BetterHelp segments, credit agreements, equity plans, and governance changes, while still being able to open the full SEC documents for complete details.
Teladoc Health’s Chief Accounting Officer reported routine equity transactions in company stock. On 01/02/2026, restricted stock units converted into 2,083 shares of Teladoc Health common stock on a one-for-one basis. On 01/05/2026, the officer sold 758 shares at $7.145 per share to cover tax withholding obligations related to the vesting of restricted stock units.
After these transactions, the officer held 6,686 shares of Teladoc Health common stock directly and 14,584 restricted stock units. The filing notes that an earlier grant of 25,000 restricted stock units from October 1, 2024 vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health director reports RSU conversion into common stock. On 12/19/2025, the reporting person converted 1,016 restricted stock units into an equal number of Teladoc Health common shares, increasing directly held common stock to 9,145 shares. A related derivative line shows 1,016 restricted stock units being settled for 1,016 common shares at an exercise price of $0, leaving 3,050 restricted stock units beneficially owned.
The filing notes that these restricted stock units were originally granted on September 20, 2023, in an award of 12,195 units that vest one‑third on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health, Inc. disclosed that board member J. Eric Evans plans to retire from its Board of Directors. He informed the company on December 11, 2025 that he will not stand for reelection at Teladoc Health’s 2026 Annual Meeting of Stockholders and will retire from the Board at the conclusion of that meeting.
Mr. Evans has served as a director since 2023. The company notes that he is retiring for personal reasons and that his decision is not due to any disagreement with Teladoc Health on any matter.
Teladoc Health, Inc. reported that on December 9, 2025 it amended its 2023 Employment Inducement Incentive Award Plan. The amendment increases the number of shares of common stock reserved for issuance under the 2023 Inducement Plan by 1,780,000 shares, bringing the total reserve to 7,280,000 shares of common stock.
This plan is used to grant equity awards to new employees as inducement for joining the company. Teladoc notes that the 2023 Inducement Plan was adopted by the Board without stockholder approval in reliance on NYSE Rule 303A.08, which permits certain inducement awards without a shareholder vote.
Teladoc Health’s chief executive officer reported new stock activity in a Form 4 filing. On December 10, 2025, 39,160 restricted stock units vested and converted into the same number of shares of Teladoc common stock. On December 11, 2025, the CEO sold 17,138 shares of common stock at an average price of $7.6343 per share to cover tax withholding obligations tied to this vesting.
After these transactions, the CEO directly owned 201,036 shares of Teladoc common stock and held 234,963 restricted stock units. The restricted stock units referenced stem from a grant of 469,924 units made on June 10, 2024, which vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments.
Teladoc Health insider plans to sell recently vested shares. A holder has filed notice to sell 17,138 shares of Teladoc Health common stock through Fidelity Brokerage Services on or about 12/11/2025, with an aggregate market value of $130,836.63. The filing notes that 177,473,405 Teladoc shares were outstanding, giving context for the size of this planned sale.
The 17,138 shares to be sold were acquired on 12/10/2025 via restricted stock vesting as compensation from the issuer. The same seller, Charles Divita, previously sold 16,787 Teladoc common shares on 09/11/2025 for gross proceeds of $127,435.15. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about Teladoc’s operations.
Teladoc Health, Inc. insider equity activity: A company officer, the President of BetterHelp, reported multiple stock transactions in early December 2025. On December 1, 2025, the officer exercised restricted stock units that converted on a one-for-one basis into 5,491 shares of Teladoc common stock and an additional 1,042 shares, both at an exercise price of $0, reflecting vesting of prior equity awards.
On December 2, 2025, the officer sold 2,324 shares of common stock at $7.488 per share to cover tax withholding obligations related to the vesting. On December 3, 2025, a further 4,209 shares were sold at $7.48 per share pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024 and amended on November 27, 2024. Following these transactions, the form shows remaining holdings in restricted stock units, including 21,966 and 5,210 units from prior grants that continue to vest over time.
Teladoc Health’s chief legal officer and secretary reported routine stock activity related to vesting of prior equity awards. On December 1, 2025, 1,505 performance stock units and two blocks of restricted stock units (4,418 and 5,350 units) converted on a one-for-one basis into shares of Teladoc common stock. On December 2, 2025, 5,720 common shares were sold at $7.488 per share to satisfy tax withholding obligations tied to these vesting events. After these transactions, the officer directly owns 80,732 shares of common stock and continues to hold derivative awards, including performance and restricted stock units scheduled to vest over time.
Teladoc Health insider equity activity: A Teladoc Health officer, identified as President, International, reported routine equity compensation transactions involving company common stock. On December 1, 2025, the officer acquired 1,056 shares of Teladoc common stock through performance stock units converting on a one-for-one basis and an additional 3,101 shares and 4,556 shares through restricted stock units that also convert one-for-one into common stock. These awards stem from prior grants made in March 2023 and March 2024 with scheduled vesting over time.
On December 2, 2025, the officer sold 3,897 shares of Teladoc common stock at a price of $7.488 per share to cover tax withholding obligations related to the vesting of the performance and restricted stock units. Following these transactions, the officer continued to hold tens of thousands of Teladoc shares directly, reflecting ongoing equity ownership linked to prior stock unit grants.
Teladoc Health, Inc. officer reports stock unit vesting and tax-sale transaction. A Teladoc Health executive, serving as President, U.S. Group Health, reported the conversion of performance stock units and restricted stock units into common stock and a related sale of shares.
On 12/01/2025, 1,189 performance stock units and two blocks of restricted stock units totaling 8,346 units (3,488 and 4,858) converted into the same number of Teladoc common shares on a one-for-one basis. On 12/02/2025, 4,582 shares of common stock were sold at $7.488 per share to cover tax withholding obligations from these vestings.
After these transactions, the reporting person beneficially owned 60,054 shares of Teladoc common stock directly, along with remaining derivative holdings that include performance and restricted stock units scheduled to vest over time under prior grants.
FAQ
What is the current stock price of Teladoc Health (TDOC)?
What is the market cap of Teladoc Health (TDOC)?
